Dyne Therapeutics (NASDAQ:DYN) Given Buy Rating at Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN - Free Report) in a research report released on Monday morning,Benzinga reports. Chardan Capital currently has a $50.00 price objective on the stock.

Several other analysts have also recently commented on DYN. Robert W. Baird started coverage on Dyne Therapeutics in a research report on Friday, December 13th. They issued an "outperform" rating and a $46.00 target price for the company. Scotiabank assumed coverage on Dyne Therapeutics in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $50.00 price objective for the company. Piper Sandler lowered their target price on Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. Guggenheim reissued a "buy" rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. Finally, Royal Bank of Canada restated an "outperform" rating and set a $45.00 price target on shares of Dyne Therapeutics in a report on Tuesday, January 14th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $47.46.

Remove Ads

Dyne Therapeutics Trading Down 1.5 %

Shares of Dyne Therapeutics stock traded down $0.18 on Monday, reaching $12.08. 2,328,438 shares of the company were exchanged, compared to its average volume of 1,342,075. Dyne Therapeutics has a fifty-two week low of $11.18 and a fifty-two week high of $47.45. The firm has a market capitalization of $1.37 billion, a price-to-earnings ratio of -3.39 and a beta of 1.11. The stock has a fifty day moving average price of $13.68 and a 200-day moving average price of $24.49.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.92) by $0.04. On average, equities analysts anticipate that Dyne Therapeutics will post -3.44 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Oxana Beskrovnaya sold 2,598 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total value of $36,242.10. Following the completion of the sale, the insider now directly owns 199,087 shares in the company, valued at approximately $2,777,263.65. The trade was a 1.29 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold 6,237 shares of company stock valued at $77,760 over the last three months. 20.77% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Dyne Therapeutics

A number of institutional investors have recently modified their holdings of DYN. US Bancorp DE boosted its holdings in shares of Dyne Therapeutics by 776.9% during the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company's stock worth $49,000 after buying an additional 1,212 shares during the period. State of New Jersey Common Pension Fund D acquired a new position in Dyne Therapeutics during the 3rd quarter worth $1,588,000. Victory Capital Management Inc. boosted its holdings in Dyne Therapeutics by 59.4% during the third quarter. Victory Capital Management Inc. now owns 30,537 shares of the company's stock valued at $1,097,000 after acquiring an additional 11,385 shares during the period. Oppenheimer & Co. Inc. grew its position in shares of Dyne Therapeutics by 4.3% in the third quarter. Oppenheimer & Co. Inc. now owns 40,091 shares of the company's stock valued at $1,440,000 after purchasing an additional 1,636 shares during the last quarter. Finally, KBC Group NV increased its stake in shares of Dyne Therapeutics by 53.4% in the third quarter. KBC Group NV now owns 2,157 shares of the company's stock worth $77,000 after purchasing an additional 751 shares during the period. Institutional investors own 96.68% of the company's stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.